Work

MaaT013 for ruxolitinib-refractory acute graft-versus-host disease with gastrointestinal involvement: Results from the ARES phase III trial

Year: 2025

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2025-817

Authors: Florent Malard, Jaime Sanz, Clemence Mediavilla, Lucia Lopez-Corral, Alexander Schauwvlieghe, Marc Bernard, Michael Loschi, Sylvie François, Francesca Bonifazi, Daniela Heidenreich, Marion Bruelle, Behzad Kharabi Masouleh, Emilie Plantamura, Ernst Holler, Mohamad Mohty

Institutions: Inserm, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Antoine, Centre de Recherche Saint-Antoine, Universitat de València, Hospital Universitari i Politècnic La Fe, Centro de Investigación Biomédica en Red de Cáncer, Centre Hospitalier Universitaire de Bordeaux, Complejo Hospitalario de Salamanca, Centre Hospitalier Universitaire de Rennes, Centre Hospitalier Universitaire de Nice, Centre Hospitalier Universitaire d'Angers, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, MaaT Pharma (France), University of Regensburg

Language: English

Topic: Hematopoietic Stem Cell Transplantation

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4417017275

Cites:

Cited by: 8

Related to: